- Home
- UCAR vs LPCN Comparison
UCAR vs LPCN Comparison
Compare UCAR & LPCN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- UCAR
- LPCN
- Stock Information
- Founded
- UCAR 2013
- LPCN 1997
- Country
- UCAR China
- LPCN United States
- Employees
- UCAR 80
- LPCN N/A
- Industry
- UCAR Retail-Auto Dealers and Gas Stations
- LPCN Biotechnology: Pharmaceutical Preparations
- Sector
- UCAR Consumer Discretionary
- LPCN Health Care
- Exchange
- UCAR Nasdaq
- LPCN Nasdaq
- Market Cap
- UCAR 13.3M
- LPCN 16.1M
- IPO Year
- UCAR 2023
- LPCN N/A
- Fundamental
- Price
- UCAR $3.15
- LPCN $3.11
- Analyst Decision
- UCAR
- LPCN Strong Buy
- Analyst Count
- UCAR 0
- LPCN 2
- Target Price
- UCAR N/A
- LPCN $9.00
- AVG Volume (30 Days)
- UCAR 19.1K
- LPCN 71.7K
- Earning Date
- UCAR 06-17-2025
- LPCN 05-08-2025
- Dividend Yield
- UCAR N/A
- LPCN N/A
- EPS Growth
- UCAR N/A
- LPCN N/A
- EPS
- UCAR N/A
- LPCN N/A
- Revenue
- UCAR $6,067,871.00
- LPCN $3,674,834.00
- Revenue This Year
- UCAR N/A
- LPCN N/A
- Revenue Next Year
- UCAR N/A
- LPCN N/A
- P/E Ratio
- UCAR N/A
- LPCN N/A
- Revenue Growth
- UCAR 124.09
- LPCN N/A
- 52 Week Low
- UCAR $2.30
- LPCN $2.68
- 52 Week High
- UCAR $9.43
- LPCN $11.79
- Technical
- Relative Strength Index (RSI)
- UCAR 59.14
- LPCN 46.04
- Support Level
- UCAR $3.05
- LPCN $3.00
- Resistance Level
- UCAR $3.41
- LPCN $3.49
- Average True Range (ATR)
- UCAR 0.22
- LPCN 0.34
- MACD
- UCAR 0.01
- LPCN -0.05
- Stochastic Oscillator
- UCAR 69.23
- LPCN 22.33
About UCAR U Power Limited
U Power Ltd is involved in the provision of vehicle sourcing services. It is principally engaged in the provision of new energy vehicles development and sales; battery swapping stations manufacturing and sales; battery swapping services, and sourcing services. The company, as a broker, engaged in sales of vehicles between automobile wholesalers and buyers, including small and medium-sized vehicle dealers and individual customers located in lower-tier cities in China.
About LPCN Lipocine Inc.
Lipocine Inc is a clinical-stage biopharmaceutical company, that is engaged in research and development for the delivery of drugs using its proprietary delivery technology. Its principal operation is to provide oral delivery solutions for existing drugs. Lipocine develops its drug candidates or it develops drug candidates on behalf of or in collaboration with corporate partners. The company's product TLANDO is an oral testosterone replacement therapy ("TRT"). It also has other products in the pipeline such as LPCN 1144, TLANDO, TLANDO XR, LPCN 1148, LPCN 1107, LPCN 1154, and LIP'RAL7 Technology. The Company has a single reportable segment, research, and development for the delivery of drugs using its proprietary delivery technology.